Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 2Head & Neck 1

Conditions

Prostatic Neoplasms 2Salivary Gland Adenoma, Pleomorphic 1Recurrence 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Isoflavones × Genitourinary × Clear all
NCT00499408 2018-11-21

Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer

Wake Forest University Health Sciences

Phase 2 Completed
26 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT00596895 2011-09-20

Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer

University of Florida

Phase 2 Completed
20 enrolled
GenitourinaryHead & Neck

Salivary Gland Adenoma, Pleomorphic, Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡